Mergers

Akorn to Acquire Hi-Tech Pharmacal for $640 Million

LAKE FOREST, Ill.--(BUSINESS WIRE)-- Akorn, Inc. (NASDAQ: AKRX) and Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that they have entered into a definitive agreement under which Akorn will acquire Hi-Tech for $640 million in cash.

AstraZeneca's MedImmune Division to Acquire Amplimmune

AstraZeneca (NYSE: AZN) today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.

Amgen To Acquire Onyx Pharma For $10.4 Billion

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., PRNewswire-- Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash.

Romaco Group Holding Company Buys Tablet Press Maker

International Process and Packaging Technologies GmbH (IPPT) has announced the purchase of Kilian GmbH & Co. KG, a Cologne-based international supplier of tablet press machines with reported sales of approximately 45 million euros in 2012.
IPPT is a portfolio company of Deutsche Beteiligungs AG (DBAG) and owner of the Romaco Group, with production sites in Germany, Switzerland and Italy as well as Sales & Service Centres in the US, Spain and Brazil.

AntriaBio Completes Merger With Nevada Corporation

The new company will focus on developing treatment for diabetes patients.

AntriaBio Delaware, Inc. f/k/a AntriaBio, Inc. ("AntriaBio Delaware"), a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the closing of its planned and previously announced merger with AntriaBio, Inc. f/k/a Fits My Style Inc., a Nevada corporation. Following the merger, the company is now listed as AntriaBio, Inc. ("AntriaBio"), and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY." In connection with the merger, AntriaBio appointed three new directors.

No votes yet

Sanofi, Bristol-Myers Squibb to Restructure Alliance

The two pharma firms altered their partnership following the loss of exclusivity of some drugs in many major markets.

Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

No votes yet

PharmaLive Special Report: The Impact of a Sanofi-Aventis/Genzyme Merger

The Paris-based pharma behemoth, Sanofi-Aventis, leads the second-largest health-care acquisition of 2010 with its proposed purchase of Genzyme Corp., one of the world’s leading biotech players. The European Union has recently announced its approval for the proposed $18.5 billion deal, however, the deal has been held up as Genzyme considers the $69 per share offer as too low. Industry insiders speculate that this deal will soon be worked out.
 

Alcon Starts Lawsuit Trust, Focuses On Novartis

From Associated Press (July 8, 2010)

NEW YORK -- Alcon Inc.’s Independent Director Committee said Thursday it created a litigation trust with $50 million for litigation related to any deal between Alcon and a majority shareholder, with a focus on Novartis.

The trust was formed to provide funds to commence, defend or maintain a lawsuit. Novartis currently owns about 23 percent of Alcon and is trying to buy the company. It has offered up to $39 billion for Alcon.

Syndicate content